Últimas noticias sobre Moderna (NASDAQ:MRNA) Bolsa

Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Volatilidad

Markets

Media

GRAL

MRNA

Volatilidad y nerviosismo sacuden los mercados por las políticas comerciales impredecibles de Trump. ¿Qué podría pasar ahora?

Analistas advierten impacto financiero si Trump no redefine su estrategia comercial pronto

Xpeng, Hesai Group, Kohl's, Groupon, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

Equities

News

$BTC

DOMH

LCID

NVDA

TSLA

El mercado bursátil de Estados Unidos enfrentó una jornada complicada ayer, ya que el sentimiento de riesgo continuó bajo presión en Wall Street. El índice S&amp;P 500 vivió una sesión volátil, alcanzando su punto más bajo en más de seis meses antes de recuperar parte de sus pérdidas.

Nvidia, Moderna, Lucid, Dominari, Tesla: 5 acciones que están en el radar de los inversores

Large Cap

Health Care

General

CVAC

NVAX

Un trabajador lechero en Nevada da positivo en gripe aviar H5N1. CDC investiga mientras la cepa se propaga en aves y ganado.

Gripe aviar en EE.UU.: trabajador lechero en Nevada da positivo

Moderna Inc

The President Donald Trump administration&#8217;s request for Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) to conduct new clinical trials for its COVID-19 vaccine.
What Happened: Novavax announced Monday that the Food and Drug Administration requested a new clinical trial before granting full approval for its protein-based COVID-19 shot, despite the company believing its vaccine remains &#8220;approvable.&#8221; 
The requirement came shortly after FDA Commissioner Marty Makary characterized the annually updated vaccine as &#8220;a new product&#8221; requiring new studies.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">To be clear, this is a new product that Novavax is trying to introduce to the market with a study of a different product from 2021. New products require new clinical studies. Under this administration, we are prioritizing the Gold Standard of Science&#8211;not what saves pharma… <a href="https://t.co/1f7NvJ9qEJ">pic.twitter.com/1f7NvJ9qEJ</a>
&mdash; Dr. Martin Makary (@DrMakaryFDA) <a href="https://twitter.com/DrMakaryFDA/status/1916253910039429309?ref_src=twsrc%5Etfw">April 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The situation developed following leadership changes at the FDA, including the departure of the agency&#8217;s longtime Vaccine Chief over disagreements with Health Secretary Robert F. Kennedy Jr. 
Industry experts note the FDA had been on track to approve Novavax&#8217;s application by April 1, but Trump appointees directed a pause, the Associated Press <a href="https://apnews.com/article/vaccine-novavax-fda-trump-covid-study-4b4465ad77cfb0554b27b7d59c40ae32">reported</a>, citing anonymous sources.
See Also: <a href="https://www.benzinga.com/general/entertainment/25/04/45059675/mrbeast-sparks-outrage-with-100-men-vs-gorilla-post-on-elon-musks-x-peta-claps-back-try-100-reasons-to-leave-animals">MrBeast Sparks Outrage With &#8216;100 Men Vs Gorilla&#8217; Post On Elon Musk&#8217;s X — PETA Claps Back: &#8216;Try 100 Reasons To Leave Animals&#8230;&#8217;</a>
Why It Matters: A United States Department of Health and Human Services spokesman suggested all COVID-19 vaccines could face stricter requirements, stating: &#8220;The urgency to rush approval of boosters without normal oversight no longer exists.&#8221;
Preliminary results from <a href="https://www.benzinga.com/general/biotech/25/04/44824383/novavax-covid-vaccine-shows-milder-side-effects-than-pfizer-biontechs-shot-study">the SHIELD-Utah study</a> showed Novavax&#8217;s 2024-2025 formula targeting the JN.1 strain produced fewer and less severe side effects compared to Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and BioNTech SE&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) mRNA shots.
Former Health Secretary Xavier Becerra defended the safety record of COVID-19 vaccines, noting: &#8220;We had put some 700 million COVID vaccines into the arms of Americans. That&#8217;s a pretty good size clinical trial.&#8221;
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/insider-trades/25/04/45059696/airbnb-billionaire-joe-gebbia-buys-over-1-million-worth-of-tsla-stock-ahead-of-elon-musks-robotaxi-launch-in-june">Airbnb Billionaire Joe Gebbia Buys Over $1 Million Worth Of TSLA Stock Ahead Of Elon Musk&#8217;s Robotaxi Launch In June</a></li>
</ul>
Image Via Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

BNTX

Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline

Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna.
Looking at options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) we detected 13 trades.
If we consider the specifics of each trade, it is accurate to state that 53% of the investors opened trades with bullish expectations and 23% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $1,183,210 and 7, calls, for a total amount of $341,156.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $22.5 to $40.0 for Moderna over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Moderna's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Moderna's whale activity within a strike price range from $22.5 to $40.0 in the last 30 days. 
<h3>Moderna Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745607651_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$3.8</td>
<td>$3.6</td>
<td>$3.7</td>
<td>$25.00</td>
<td>$832.5K</td>
<td>10.8K</td>
<td>20</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$3.65</td>
<td>$3.55</td>
<td>$3.55</td>
<td>$25.00</td>
<td>$127.0K</td>
<td>10.8K</td>
<td>2.6K</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$6.55</td>
<td>$6.25</td>
<td>$6.33</td>
<td>$22.50</td>
<td>$63.3K</td>
<td>1.7K</td>
<td>350</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$6.35</td>
<td>$6.3</td>
<td>$6.35</td>
<td>$22.50</td>
<td>$62.8K</td>
<td>1.7K</td>
<td>450</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$3.65</td>
<td>$3.5</td>
<td>$3.55</td>
<td>$25.00</td>
<td>$62.1K</td>
<td>10.8K</td>
<td>2.9K</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Having examined the options trading patterns of Moderna, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Moderna Standing Right Now?</h3>
<ul>
<li>With a volume of 4,280,961, the price of MRNA is up 0.49% at $27.52. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 6 days.</li>
</ul>
<h3>What Analysts Are Saying About Moderna</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $32.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley persists with their Equal-Weight rating on Moderna, maintaining a target price of $32. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Moderna, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Behind the Scenes of Moderna's Latest Options Trends

Stocks in the U.S. were trading sharply lower by midday Monday, while gold and Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) surged in tandem, as a renewed political storm surrounding Federal Reserve independence shook confidence in the U.S. dollar and triggered a broad-based risk-off <a href="https://www.benzinga.com/government/regulations/25/04/44899280/are-investors-selling-us-treasuries-as-trump-attacks-powell-heres-what-latest-etf-flows-tell-you">mood on U.S. assets.</a>
The market opened the post-Easter trading week with deep losses, after President Donald Trump took to Truth Social demanding immediate rate cuts and blasting Fed Chair Jerome Powell as "Mr. Too Late," accusing him of past political bias and inflation misjudgment. 
Trump wrote that there's "virtually no inflation" and warned of an economic slowdown unless Powell acts "NOW."
The latest barrage reignited fears that central bank independence may be under direct threat, just days after reports emerged that the Trump administration is weighing Powell's removal ahead of his scheduled 2026 term expiration.
The U.S. Dollar Index (DXY) fell as much as 1%, marking its lowest level since early 2022, as the greenback weakened against a basket of major currencies including the Japanese yen, euro and Swiss franc. 
The selloff has intensified speculation that foreign investors may accelerate the repatriation of capital from U.S. assets amid mounting political and monetary instability.
The S&amp;P 500 dropped 2.8% by midday, with the Nasdaq 100 falling 3%, led lower by steep losses in megacap tech and financials. Every major sector was in the red, with 490 of the 500 S&amp;P 500 stocks trading lower.
In another break from historical norms, U.S. Treasury yields climbed even as equities tanked and volatility spiked. The 30-year yield rose 7 basis points to 4.87%, signaling investor selling of government debt. The CBOE Volatility Index (VIX) jumped 15%. 
Gold-linked equities were the few bright spots in an otherwise brutal session. Gold prices – as tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) – surged 2.6% to $3,410 per ounce, pushing the year-to-date gain to nearly 30%—on track for the metal's best annual performance since 2007. 
The move extends gold's stunning 2-month rally, now nearing 20%, amid persistent demand for safe-haven assets.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) gained 3.5% to trade at $88,274, echoing gold's momentum as investors seek alternatives to fiat currencies.
Monday&#8217;s Performance In Major US Indices, ETFs
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg (%)</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,837.81</td>
<td>-2.3%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>38,097.81</td>
<td>-2.7%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,135.83</td>
<td>-2.8%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>17,727.70</td>
<td colspan="2">-3.0%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:20 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 2.8% up to $511.49.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) fell 2.7% to $380.65.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;tumbled 3% to $430.76.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 2.3% to $182.28.</li>
<li>The&nbsp;Consumer Staples&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) outperformed, yet falling 1.4%; the&nbsp;Consumer Discretionary&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) lagged, down 3.5%.</li>
</ul>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Top Performers On Monday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company Name</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fidelity National Information Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>)</td>
<td>3.81%</td>
</tr>
<tr>
<td>Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>)</td>
<td>2.89%</td>
</tr>
<tr>
<td>Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>)</td>
<td>1.75%</td>
</tr>
<tr>
<td>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)</td>
<td>1.02%</td>
</tr>
<tr>
<td>Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>)</td>
<td>0.86%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Worst Performers On Monday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company Name</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Universal Health Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>)</td>
<td>-10.31%</td>
</tr>
<tr>
<td>Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>)</td>
<td>-8.34%</td>
</tr>
<tr>
<td>Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>)</td>
<td>-8.23%</td>
</tr>
<tr>
<td>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)</td>
<td>-7.48%</td>
</tr>
<tr>
<td>Blackstone Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>)</td>
<td>-7.42%</td>
</tr>
</tbody>
</table>
</figure>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/news/25/04/44886209/if-you-had-bet-on-gold-after-the-1971-nixon-shock-youd-have-beaten-the-sp-500-unless-you-did-this-one-thing">If You Had Bet On Gold After The 1971 Nixon Shock, You&#8217;d Have Beaten The S&amp;P 500 — Unless You Did This One Thing</a></li>
</ul>
Photo: FOTOGRIN/Shutterstock

Government

Regulations

Broad U.S. Equity ETFs

Econ #s

Federal Reserve

ETFs

SPDR Dow Jones Industrial Average ETF Trust

NFLX

ULTA

Select Sector SPDR-Consumer Discretionary

Wall Street Sinks, Dollar Slides As Trump Ramps Up Fed Attacks: What's Driving Markets Monday?

On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">respiratory tract disease (LRTD)</a>.
In June 2024, ACIP postponed a vote on a recommendation for adults aged 50-59 at increased risk for RSV-LRTD until additional <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39522040/cdc-advisor-panel-recommends-rsv-shots-in-us-for-people-above-75-years-analyst-says-decision-nega" rel="noreferrer noopener">data becomes available</a>.
The update includes Pfizer Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Abrysvo (Respiratory Syncytial Virus Vaccine), which the U.S. Food and Drug Administration approved in October 2024 for the prevention of RSV-associated LRTD in adults aged 18 to 59 at increased <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41493556/fda-approves-pfizers-respiratory-syncytial-virus-vaccine-abrysvo-for-adults-below-60-years" rel="noreferrer noopener">risk of severe disease</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction" rel="noreferrer noopener">Trump&#8217;s New Order Targets Drug Pricing Transparency And Medicare Cost Reduction</a>
The recommendation also includes GSK plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Arexvy in adults aged 50-59 who are at increased risk <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44853850/arexvy-recommended-for-adults-aged-50-59-at-increased-risk-for-severe-respiratory-syncytial-virus-" rel="noreferrer noopener">for severe RSV disease</a>.
This expands on ACIP&#8217;s previous vote in June 2024 to recommend RSV vaccines for adults aged 60-74 who are at increased risk and all adults aged 75 and older.
Arexvy is indicated for the prevention of LRTD caused by RSV in individuals 60 years of age and older and individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV.
According to the CDC, between 15,000 &#8211; 20,000 RSV-associated hospitalizations occur annually in U.S. adults <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44852139/acip-votes-to-expand-recommendation-for-pfizers-rsv-vaccine-abrysvo-to-include-adults-aged-50-to-5" rel="noreferrer noopener">aged 50 &#8211; 59 years</a>.
A systematic review of studies in the U.S. shows that RSV is estimated to cause 42,000 hospitalizations each year in adults aged 50-64 years old.
GSK said the ACIP considered results from a phase 3 trial evaluating the immune response and safety of GSK&#8217;s RSV vaccine in adults aged 50-59, including those at increased risk for RSV-LRTD due to certain underlying medical conditions compared to older adults aged 60 years and older where efficacy has been demonstrated after a single dose of GSK&#8217;s RSV vaccine.
The updated recommendation does not benefit Moderna Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) mRNA-based RSV vaccine mRESVIA (mRNA-1345), which is currently approved for adults over 60 years.
William Blair notes Moderna shared Phase 3 data for mRNA-1345 in high-risk adults aged 18-59 at its 2024 R&amp;D Day event and has since submitted an application to the FDA for regulatory approval using a priority review voucher.&nbsp;The FDA <a target="_blank" href="https://investors.modernatx.com/news/news-details/2025/Moderna-Reports-Fourth-Quarter-and-Fiscal-Year-2024-Financial-Results-and-Provides-Business-Updates/default.aspx" rel="noreferrer noopener">has</a> accepted Moderna&#8217;s application and has assigned a PDUFA goal date of June 12, 2025.
Analyst Myles R. Minter highlights the Phase 3 trial of mRNA-1345 in over 1,000 high-risk individuals between ages 18 and 59. mRNA-1345 demonstrated non-inferior immunogenicity compared to adults age 60 or older for neutralizing antibodies against both RSV-A and RSV-B and a tolerable safety profile.
&#8220;If approved on time, we believe mRESVIA could be added to the updated age group recommendation during the scheduled June 25-26, 2025, ACIP meeting,&#8221; Minter said.
Price Action: PFE stock is up 1.07% 22.28, MRNA stock is down 2.30% at $24.62, and GSK stock is up 1.74% at $35.98 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44860903/eli-lillys-oral-glp-1-drug-orforglipron-hits-phase-3-goals-in-diabetes-trial-stock-shoots-higher" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s Oral GLP-1 Drug Orforglipron Hits Phase 3 Goals In Diabetes Trial, Stock Soars</a></li>
</ul>
Photo by pedro7merino via Shutterstock

Biotech

US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years

WIIM

DVAX

PCVX

Shares of vaccine stocks are trading lower after CDC advisers begins a review of vaccine guidelines and discussed a more narrow use of COVID-19 booster shots.

Wall Street gained ground by midday trading on Tuesday, as investor concerns over the economic impact of trade tensions continued to ease following recent signs that the Trump administration was taking <a href="https://www.benzinga.com/government/regulations/25/04/44812727/bessent-says-tariffs-on-china-are-far-from-a-joke-dismisses-treasury-dumping-fears">a more conciliatory approach.</a>
All major indexes were in positive territory, with tech stocks leading the way thanks to strong performances by Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) and Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), both rising about 6%.
The streaming giant climbed following a <a href="https://www.wsj.com/business/media/netflix-aims-to-join-the-1-trillion-club-fdacb250">Wall Street Journal report</a> that it plans to double revenue by 2030, citing sources. Netflix is set to release its first-quarter earnings on Thursday after market close.
The S&amp;P 500 has now recovered nearly 80% of the losses suffered after Trump's tariff announcement on April 2.
Among sectors, financials led the gains, climbing 1.3%, supported by strong earnings reports from Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) and Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), which surged 4.3% and 3.8%, respectively.
The U.S. Dollar Index (DXY) rebounded 0.5%, aiming to end a five-day losing streak, while Treasury yields declined further, easing fears of a potential sell-off of U.S. assets by foreign investors. Yields on the 10-year Treasury fell five basis points to 4.33%, following an 11-basis-point drop on Monday.
In commodities, gold edged up 0.4% to $3,223 per ounce, while oil prices slipped 0.8% to $61 per barrel. Natural gas dropped 1.6% to $3.25 per million British thermal units, approaching its lowest level since mid-December 2024.
Crypto markets remained relatively quiet, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rising 0.5% to $85,000.
<h1 class="wp-block-heading">Tuesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day chg %</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,934.51</td>
<td>0.7%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,888.28</td>
<td>0.4%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,424.34</td>
<td>0.3%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>40,639.56</td>
<td>0.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:20 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.3% to $540.87.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) inched 0.1% higher to $405.36.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;increased 0.7% to $460.14.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) edged 0.4% higher to $187.22.</li>
<li>The&nbsp;Financial&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) outperformed, up 1.3%; the&nbsp;Health Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 0.5%.</li>
</ul>

<h1 class="wp-block-heading">S&amp;P 500&#8217;s Top 5 Gainers On Monday</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Netflix, Inc. </td>
<td>5.88%</td>
</tr>
<tr>
<td>Palantir Technologies Inc.</td>
<td>5.18%</td>
</tr>
<tr>
<td>Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>)</td>
<td>4.87%</td>
</tr>
<tr>
<td>CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>)</td>
<td>4.53%</td>
</tr>
<tr>
<td>Bank of America Corporation </td>
<td>4.38%</td>
</tr>
</tbody>
</table>
</figure>
<h1 class="wp-block-heading">S&amp;P 500&#8217;s Worst 5 Losers On Monday</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albemarle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)</td>
<td>-4.25%</td>
</tr>
<tr>
<td>Molina Healthcare, Inc. (NYSE: МОH)</td>
<td>-3.66%</td>
</tr>
<tr>
<td>Zimmer Biomet Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>)</td>
<td>-3.14%</td>
</tr>
<tr>
<td>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)</td>
<td>-2.94%</td>
</tr>
<tr>
<td>The Campbell&#8217;s Company (NYSE: СРB)</td>
<td>-2.75%</td>
</tr>
</tbody>
</table>
</figure>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44817677/citigroup-ceo-jane-fraser-bets-us-will-still-be-worlds-leading-economy-and-dollar-the-reserve-currency-after-trade-uncertainty-settles">Citigroup CEO Jane Fraser Bets US Will &#8216;Still Be World&#8217;s Leading Economy&#8217; And Dollar &#8216;The Reserve Currency&#8217; After Trade Uncertainty Settles</a></li>
</ul>

Earnings

Macro Economic Events

Mid Cap

Sector ETFs

Economics

Tech

CRWD

PLTR

Stocks Edge Up On Strong Bank Earnings, Netflix Soars, Dollar Rebounds: What's Driving Markets Tuesday?

Robert F. Kennedy Jr., the nation&#8217;s top health official, questioned whether society should bear the cost of healthcare for individuals who engage in unhealthy habits, such as smoking or consuming doughnuts.
What Happened: In an interview <a href="https://www.cbsnews.com/news/rfk-jr-sweeping-cuts-health-programs-employees-exclusive-interview/">with</a> CBS News, Kennedy asked, "If you're smoking three packs of cigarettes a day, should you expect society to pay when you get sick?"
He emphasized that while Americans have the freedom to make such choices, the question remains whether society should cover the resulting health care costs.
Public health experts expressed concern, suggesting Kennedy&#8217;s remarks could imply limiting access to health care based on personal behavior.
See Also: <a href="https://www.benzinga.com/25/04/44777097/gm-halts-electric-van-production-in-ontario-amid-sluggish-sales-1200-employees-affected">GM Halts Electric Van Production In Ontario Amid Sluggish Sales: 1,200 Employees Affected</a>
Meanwhile, the Department of Health and Human Services (DHHS) clarified that Kennedy aims to empower individuals with better health options, not to shame them.
His comments, they said, reflect a broader strategy to align public health outcomes with smart incentives.
Amid these discussions, Kennedy&#8217;s department has faced criticism for recent layoffs affecting programs aimed at reducing smoking, raising questions about the impact on public health efforts.
Why It Matters: This debate comes on the heels of <a href="https://www.benzinga.com/markets/25/03/44550801/rfk-jr-spreading-misinformation-and-lies-fdas-top-vaccine-official-walks-out-sparking-debate-on-safety-an">RFK Jr.&#8217;s previous controversies</a> surrounding health policies. Recently, Peter Marks, the FDA&#8217;s top vaccine official, resigned due to Kennedy&#8217;s stance on vaccine misinformation.
Marks was integral in the COVID-19 vaccine rollout, and his departure has sparked concerns about the politicization of health decisions.
Additionally, Kennedy has been proactive in addressing health issues by <a href="https://www.benzinga.com/markets/equities/25/03/44209953/rfk-jr-takes-on-food-giants-calls-meeting-with-pepsico-and-general-mills">engaging</a> with major food companies. In March, he called a meeting with executives from PepsiCo Inc. and General Mills Inc., urging them to address their role in public health challenges.
Earlier in February, a media report stated that the Trump administration is <a href="https://www.benzinga.com/25/02/43999106/trumps-officials-to-re-consider-modernas-590-million-bird-flu-vaccine-funding-hhs-cites-biden-administrations-failed-oversight">planning to reconsider</a> $590 million in funding for Moderna Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) bird flu vaccine, with RFK Jr.&#8217;s HHS slamming the Biden administration for a lack of oversight.
Read Next:
<ul>
<li><a href="https://benzinga.com/25/04/44774499/wall-street-panic-extends-to-main-street-as-us-china-trade-war-escalates-bond-vigilantes-make-a-comeback-this-wee">Wall Street Panic Extends To Main Street As US-China Trade War Escalates, Bond Vigilantes Make A Comeback: This Week In Markets</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Politics

RFK Jr Asks If Taxpayer-Funded Healthcare Should Be Accessible To People Smoking 'Three Packs A Day'

Wall Street ended the week on a strong note, with major indices posting their best weekly performance in years, as traders appeared confident that the escalation in the U.S.-China trade war — which led to triple-digit tariff increases on both sides — would be resolved in the near term.
Not even a shocking University of Michigan survey on consumer sentiment — revealing the most pronounced stagflation concerns in decades — nor fears of stress in the Treasury market were enough to curb the surge in dip-buying activity that emerged in the final <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44764554/consumer-sentiment-crashes-to-3-year-lows-as-inflation-expectations-spike-to-1981-highs">day of the week.</a>
<h1 class="wp-block-heading">Wall Street Rallies, Treasury Stress Fades</h1>
The S&amp;P 500 index, as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), closed at 5,363, up 1.8% on the day and 5.7% for the week, marking its best weekly performance since October 2023.
From its lows earlier in the week, the index jumped 11% and now sits just four percentage points below the level it held prior to President Donald Trump's tariff announcement on April 2.
The Nasdaq 100 index, tracked by the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), also rose 1.8% on Friday, bringing weekly gains to 7.5% — its strongest performance since November 2022.
Since Monday's lows, tech stocks have surged 13% and are now about three percentage points below pre-tariff levels.
The Dow Jones Industrial Average, tracked by the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>), rose 1.6%, extending weekly gains to 4.9%, the best week for blue chips since October 2023.
From the week's lows, the Dow has gained about 10%, and it currently trades nearly five percentage points below the level prior to the tariff news.
Materials were the best-performing sector on Friday, with the Materials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) closing 3.5% higher, buoyed by strong rallies in mining stocks.
The VanEck Gold Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDX#NYSE">GDX</a>) jumped 5.7% on the day and nearly 20% for the week, reaching levels last seen in 2012, as gold prices continued to break record highs.
Tensions in the Treasury market, which had triggered concern in Washington earlier in the day as the 30-year yield hit 5% and the 10-year surpassed 4.5%, eased by the close. The 30-year yield retreated sharply to 4.85%, while the 10-year settled at 4.47%. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) ended in the green, up 0.54%.
Oil prices rose 2.1% to $61.50 a barrel, and copper climbed 4.8%, signaling easing fears about global economic conditions.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) also reflected the improved risk sentiment, rising more than 5% to $83,850.
<h1 class="wp-block-heading">S&amp;P 500&#8217;s Top 5 Performers</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company Name </th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monolithic Power Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>)</td>
<td>+9.74%</td>
</tr>
<tr>
<td>Newmont Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>)</td>
<td>+7.67%</td>
</tr>
<tr>
<td>Huntington Ingalls Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>)</td>
<td>+7.63%</td>
</tr>
<tr>
<td>Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)</td>
<td>+6.89%</td>
</tr>
<tr>
<td>Fastenal Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>)</td>
<td>+6.42%</td>
</tr>
</tbody>
</table>
</figure>
<h1 class="wp-block-heading">Nasdaq 100&#8217;s Top 5 Performers</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company Name </th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)</td>
<td>+10.02%</td>
</tr>
<tr>
<td>Fastenal Co.</td>
<td>+6.41%</td>
</tr>
<tr>
<td>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</td>
<td>+5.49%</td>
</tr>
<tr>
<td>Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)</td>
<td>+5.20%</td>
</tr>
<tr>
<td>Applied Materials Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>)</td>
<td>+4.83%</td>
</tr>
</tbody>
</table>
</figure>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/25/04/44772209/3-big-brand-stocks-to-lean-on-during-tariff-troubles">3 Big Brand Stocks To Lean On During Tariff Troubles</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/BOY+Suttiphong">Sutthiphong Chandaeng</a> via Shutterstock

Bonds

Commodities

Treasuries

AMAT

AVGO

FAST

Market Vectors ETF Trust Market Vectors Gold Miners

MPWR

MSTR

iShares Trust Barclays 20+ Year Treasury Bond Fund

Stocks Notch Best Week In Years As Dip Buying On Tariff Crisis Gathers Momentum

Whales with a lot of money to spend have taken a noticeably bearish stance on Moderna.
Looking at options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) we detected 13 trades.
If we consider the specifics of each trade, it is accurate to state that 23% of the investors opened trades with bullish expectations and 69% with bearish.
From the overall spotted trades, 9 are puts, for a total amount of $807,112 and 4, calls, for a total amount of $184,377.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $17.5 to $35.0 for Moderna over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Moderna's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Moderna's whale activity within a strike price range from $17.5 to $35.0 in the last 30 days. 
<h3>Moderna Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744210846_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$11.4</td>
<td>$11.15</td>
<td>$11.4</td>
<td>$35.00</td>
<td>$262.2K</td>
<td>4.0K</td>
<td align="right">235</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$4.35</td>
<td>$4.3</td>
<td>$4.3</td>
<td>$17.50</td>
<td>$107.5K</td>
<td>275</td>
<td align="right">250</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$4.3</td>
<td>$4.1</td>
<td>$4.22</td>
<td>$17.50</td>
<td>$101.2K</td>
<td>2.6K</td>
<td align="right">0</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$4.85</td>
<td>$4.75</td>
<td>$4.85</td>
<td>$22.50</td>
<td>$97.4K</td>
<td>1.8K</td>
<td align="right">260</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$3.9</td>
<td>$3.8</td>
<td>$3.9</td>
<td>$30.00</td>
<td>$73.3K</td>
<td>697</td>
<td align="right">192</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Having examined the options trading patterns of Moderna, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Moderna's Current Market Status</h3>
<ul>
<li>Trading volume stands at 2,241,618, with MRNA's price down by -0.14%, positioned at $24.61.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 22 days.</li>
</ul>
<h3>What Analysts Are Saying About Moderna</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $35.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Moderna with a target price of $32. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Underweight rating for Moderna, targeting a price of $33. 
&#x2A; An analyst from Citigroup has revised its rating downward to Neutral, adjusting the price target to $40. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Moderna, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Spotlight on Moderna: Analyzing the Surge in Options Activity

Morgan Stanley analyst Matthew Harrison maintains Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Equal-Weight and lowers the price target from $39 to $32.

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on Moderna, Lowers Price Target to $32

Moderna Will Present Research Across Multiple Infectious Disease Areas, Including COVID-19, Influenza, Respiratory Syncytial Virus, Cytomegalovirus, Norovirus, And mpox, At The European Society Of Clinical Microbiology And Infectious Diseases

Investors with a lot of money to spend have taken a bearish stance on Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRNA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 20 uncommon options trades for Moderna.
This isn't normal.
The overall sentiment of these big-money traders is split between 35% bullish and 55%, bearish.
Out of all of the special options we uncovered, 13 are puts, for a total amount of $481,932, and 7 are calls, for a total amount of $328,492.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $15.0 to $70.0 for Moderna over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Moderna's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Moderna's substantial trades, within a strike price spectrum from $15.0 to $70.0 over the preceding 30 days.
<h3>Moderna Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743610130_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$5.35</td>
<td>$5.25</td>
<td>$5.25</td>
<td>$25.00</td>
<td>$85.0K</td>
<td>184</td>
<td align="right">164</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$5.35</td>
<td>$5.25</td>
<td>$5.25</td>
<td>$25.00</td>
<td>$66.6K</td>
<td>184</td>
<td align="right">166</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$4.65</td>
<td>$4.6</td>
<td>$4.6</td>
<td>$30.00</td>
<td>$53.8K</td>
<td>6.4K</td>
<td align="right">225</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$3.45</td>
<td>$3.2</td>
<td>$3.45</td>
<td>$70.00</td>
<td>$51.4K</td>
<td>760</td>
<td align="right">150</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$2.52</td>
<td>$2.51</td>
<td>$2.52</td>
<td>$22.50</td>
<td>$47.3K</td>
<td>390</td>
<td align="right">189</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Having examined the options trading patterns of Moderna, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Moderna</h3>
<ul>
<li>With a volume of 4,613,675, the price of MRNA is up 4.86% at $28.48. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 29 days.</li>
</ul>
<h3>Professional Analyst Ratings for Moderna</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $36.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Citigroup downgraded its action to Neutral with a price target of $40. 
&#x2A; An analyst from JP Morgan has decided to maintain their Underweight rating on Moderna, which currently sits at a price target of $33. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Moderna options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Moderna Options Trading: A Deep Dive into Market Sentiment

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>IRON</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$50.00</td>
<td>$160.0K</td>
<td>4</td>
<td>2.0K</td>
</tr>
<tr>
<td>VRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$70.00</td>
<td>$55.4K</td>
<td>372</td>
<td>500</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$25.00</td>
<td>$28.3K</td>
<td>6.7K</td>
<td>302</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$310.00</td>
<td>$25.5K</td>
<td>8.7K</td>
<td>173</td>
</tr>
<tr>
<td>AKRO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$40.00</td>
<td>$25.8K</td>
<td>0</td>
<td>150</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$37.00</td>
<td>$47.8K</td>
<td>839</td>
<td>114</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$690.00</td>
<td>$37.0K</td>
<td>212</td>
<td>33</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$77.50</td>
<td>$36.0K</td>
<td>1.4K</td>
<td>26</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$470.00</td>
<td>$32.8K</td>
<td>2</td>
<td>11</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$680.00</td>
<td>$124.6K</td>
<td>10</td>
<td>11</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding IRON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>), we observe a call option trade with bearish sentiment. It expires in 16 day(s) on April 17, 2025. Parties traded 2000 contract(s) at a $50.00 strike. The total cost received by the writing party (or parties) was $160.0K, with a price of $80.0 per contract. There were 4 open contracts at this strike prior to today, and today 2000 contract(s) were bought and sold. 
• For VRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>), we notice a call option sweep that happens to be bearish, expiring in 45 day(s) on May 16, 2025. This event was a transfer of 241 contract(s) at a $70.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $55.4K, with a price of $230.0 per contract. There were 372 open contracts at this strike prior to today, and today 500 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option sweep that happens to be bearish, expiring in 290 day(s) on January 16, 2026. This event was a transfer of 59 contract(s) at a $25.00 strike. This particular put needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $28.3K, with a price of $480.0 per contract. There were 6708 open contracts at this strike prior to today, and today 302 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a call option trade with bearish sentiment. It expires in 16 day(s) on April 17, 2025. Parties traded 37 contract(s) at a $310.00 strike. The total cost received by the writing party (or parties) was $25.5K, with a price of $690.0 per contract. There were 8768 open contracts at this strike prior to today, and today 173 contract(s) were bought and sold. 
• For AKRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>), we notice a call option sweep that happens to be bullish, expiring in 16 day(s) on April 17, 2025. This event was a transfer of 150 contract(s) at a $40.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $25.8K, with a price of $170.0 per contract. There were 0 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option sweep that happens to be bearish, expiring in 108 day(s) on July 18, 2025. This event was a transfer of 90 contract(s) at a $37.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $47.8K, with a price of $532.0 per contract. There were 839 open contracts at this strike prior to today, and today 114 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a put option trade with bullish sentiment. It expires in 45 day(s) on May 16, 2025. Parties traded 30 contract(s) at a $690.00 strike. The total cost received by the writing party (or parties) was $37.0K, with a price of $1236.0 per contract. There were 212 open contracts at this strike prior to today, and today 33 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a put option trade with bearish sentiment. It expires in 290 day(s) on January 16, 2026. Parties traded 24 contract(s) at a $77.50 strike. The total cost received by the writing party (or parties) was $36.0K, with a price of $1500.0 per contract. There were 1454 open contracts at this strike prior to today, and today 26 contract(s) were bought and sold. 
• For TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we notice a call option trade that happens to be bearish, expiring in 45 day(s) on May 16, 2025. This event was a transfer of 10 contract(s) at a $470.00 strike. The total cost received by the writing party (or parties) was $32.8K, with a price of $3280.0 per contract. There were 2 open contracts at this strike prior to today, and today 11 contract(s) were bought and sold. 
• Regarding MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we observe a call option trade with bearish sentiment. It expires in 654 day(s) on January 15, 2027. Parties traded 11 contract(s) at a $680.00 strike. The total cost received by the writing party (or parties) was $124.6K, with a price of $11330.0 per contract. There were 10 open contracts at this strike prior to today, and today 11 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKRO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IRON

VRNA

10 Health Care Stocks With Whale Alerts In Today's Session

Trump Administration Health Agency Firings Include Staff Overseeing Bird Flu Response

U.S. markets continued to witness volatility on Monday as President Donald Trump&#8217;s <a href="https://www.benzinga.com/markets/equities/25/03/44554789/trumps-liberation-day-tariffs-could-fuel-inflation-after-16-trillion-fiscal-surge-lawrence-mcdonald-warns">&#8216;Liberation Day&#8217;</a> fast approaches, bringing a volley of tariffs across products, industries, allies, and adversaries. Leading analysts and experts have since urged the President to reconsider his trade policy stance.
What Happened: The market experienced another roller-coaster trading day, with the S&amp;P 500 (INDEXSP: .INX) up 0.6% at close after being down 1.7% in the morning. While this helps shave off some of its losses this quarter, it still marks the worst quarter for the index in two-and-a-half years, losing 4.6%.
The NASDAQ (INDEXNASDAQ: .IXIC) ended 0.1% lower after witnessing wild swings of nearly 3% between the highs and lows of the day, followed by the Dow Jones Industrial Average (INDEXDJX: .DJI) which closed with a 1% gain, after swerving 417 points to erase some initial losses. Both the indices are down for the quarter, with the NASDAQ losing 10.5% and the Dow Industrials 2.3%.
Among individual stocks, Discover Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) and Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) were among top gainers at 7.5% and 4.4%, respectively, while Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), Grail Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>) were among the top laggards, down 9% and 5% during the day, respectively.
Similarly, major index futures were a mixed bag on Monday evening, with Dow Futures up 1%, S&amp;P 500 Futures up 0.55%, and Nasdaq 100 down 0.14%. All of this comes in response to the uncertain global political climate and in anticipation of a messy global trade war that could disrupt all industries.
See More: <a href="https://www.benzinga.com/markets/equities/25/03/44554789/trumps-liberation-day-tariffs-could-fuel-inflation-after-16-trillion-fiscal-surge-lawrence-mcdonald-warns">Tariffs, Inflation And Tumbling Markets: These 5 ETFs Thrived Amid Last Week&#8217;s Chaos</a>
Why It Matters: Such steep curves have become routine for U.S. markets over the past couple of weeks, and there are no signs of it stopping any time soon, with seemingly no end to the uncertain trade policies of the Trump Administration, filled with false starts and abrupt changes.
Popular market voices such as Jim Cramer, who ironically <a href="https://economictimes.indiatimes.com/news/international/us/big-support-for-donald-trump-jim-cramer-shocks-wall-street-with-pro-tariff-stance-slams-free-trade-its-cost-us-fortunes/articleshow/119766832.cms?from=mdr">came out in support of the tariffs last week</a>, saying &#8216;I am pro-tariff, absolutely, I hate free trade,&#8217; is nonetheless, critical of the way the President is approaching this matter, stating that the uncertainty is taking a toll on the markets and investors.
<figure class="wp-block-embed aligncenter is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Was today one-off? Only if the President wants it to be
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1906863841600041176?ref_src=twsrc%5Etfw">April 1, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Cramer <a href="https://x.com/jimcramer/status/1906863841600041176">took to Twitter</a> again last night, addressing the wild swings in the market saying &#8216;Was today one-off? Only if the President wants it to be.&#8217; This was quite clearly aimed at the Trump Administration, asking for more certainty and clarity on trade policies going forward.
Photo Courtesy: Shutterstock.com
Read Next:
<ul>
<li> <a href="https://www.benzinga.com/news/management/25/03/44574393/ford-gm-executives-address-trump-tariffs-in-internal-memos-aimed-to-reassure-employees-report">Ford, GM Executives Address Trump Tariffs In Internal Memos Aimed To Reassure Employees: Report</a></li>
</ul>

IXIC

Jim Cramer Asks Trump To Take Stock As Markets Swing Again Ahead Of 'Liberation Day'

Editor&#8217;s Note: This story has been updated to correct an error where &#8220;Nasdaq 100&#8221; was mistakenly used instead of &#8220;Nasdaq.&#8221;
The stock market faced a challenging day as risk sentiment remained under pressure on Wall Street. The&nbsp;S&amp;P 500&nbsp;experienced a volatile session, hitting its lowest point in over six months before recovering some losses. The S&amp;P ended the day 0.5% higher at 5,611.85. Despite this, the index is on track for its worst month since September 2022, with a 7% decline in March. The Dow Jones Industrial Average was up 1% at 42,001.76 for the day.
Meanwhile, tech stocks struggled, with the Nasdaq dropping 0.14% for the day at 17,299.29 as semiconductor stocks weighed heavily on the sector.
These are the top stocks that gained the attention of retail traders and investors throughout the day.
Nvidia Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
Nvidia&#8217;s stock fell 1.18% to close at $108.38, with an intraday high of $110.96 and a low of $103.65. The stock&#8217;s 52-week range is between $153.13 and $75.61. The company announced plans to invest billions in the U.S. supply chain over the next four years. CEO Jensen Huang stated that the investment is possible due to suppliers like&nbsp;<a href="https://www.benzinga.com/25/03/44567096/nvidia-to-invest-billions-in-u-s-supply-chain-as-tech-companies-commit-to-trumps-onshoring-pledge">Taiwan Semiconductor Manufacturing Company</a>&nbsp;and Foxconn.
Moderna, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)
Moderna&#8217;s shares tumbled 8.90% to $28.35, with a high of $28.95 and a low of $26.80, marking a new 52-week low. The decline followed a shakeup at the U.S. Food and Drug Administration, with&nbsp;<a href="https://www.benzinga.com/25/03/44562368/moderna-novavax-shares-are-tumbling-monday-whats-going-on">Peter Marks</a>&nbsp;resigning from his role at the FDA's Center for Biologics Evaluation and Research.
See Also:&nbsp;<a href="https://benzinga.com/markets/25/03/44556147/mark-cuban-warns-of-red-rural-recession-as-hundreds-of-small-town-maga-supporters-reportedly-lose-federal-jobs-their-finances-will-be-turned-upside-down" target="_blank" rel="noreferrer noopener">Mark Cuban Warns Of &#8216;Red Rural Recession&#8217; As Hundreds Of Small Town MAGA Supporters Reportedly Lose Federal Jobs &#8211; Benzinga</a>
Lucid Group, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>)
Lucid&#8217;s stock rose 4.31% to $2.42, reaching a high of $2.44 and a low of $2.21. The 52-week range is $4.43 to $1.93. The increase came after bullish commentary from a company executive, who <a href="https://in.benzinga.com/25/03/44570246/whats-going-on-with-lucid-stock-today">noted</a> a "dramatic uptick" in orders from former&nbsp;Tesla Inc.&nbsp;customers.
Dominari Holdings Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOMH#NASDAQ">DOMH</a>)
Dominari&#8217;s shares fell 16.32% to $4, with a high of $5.46 and a low of $3.84. The stock&#8217;s 52-week range is $13.58 to $0.83. The decline followed the announcement of a Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://in.benzinga.com/trading-ideas/movers/25/03/44566377/whats-going-on-with-dominari-holdings-stock-monday">mining deal</a> with&nbsp;Hut 8 Corp&nbsp;and a registered direct offering.
Tesla, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
Tesla&#8217;s stock decreased by 1.67% to $259.16, with an intraday high of $260.56 and a low of $243.36. The 52-week range is $488.54 to $138.8. Despite challenges,&nbsp;Elon Musk&nbsp;remains optimistic about Tesla&#8217;s future, viewing the current situation as a <a href="https://in.benzinga.com/25/03/44557947/doge-blowback-aside-elon-musk-considers-tesla-a-solid-opportunity">buying opportunity</a>.
Image via Shutterstock
Prepare for the day&#8217;s trading&nbsp;<a href="https://editorial.benzinga.com/wp-admin/Premarket%20Movers%20&amp;%20News">with top premarket movers and news</a>&nbsp;by Benzinga.
Benzinga Edge Stock Rankings show Lucid with a 97th percentile growth score — curious how Tesla compares? <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Find out here.</a>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="695" height="105" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31225751/Screenshot-2025-04-01-at-11.57.38.png" alt="" class="wp-image-850215" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31225751/Screenshot-2025-04-01-at-11.57.38.png 695w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31225751/Screenshot-2025-04-01-at-11.57.38-300x45.png 300w" sizes="(max-width: 695px) 100vw, 695px" /></a></figure>
Read Next:&nbsp;
<ul>
<li><a href="https://benzinga.com/markets/asia/25/03/44516620/chinas-chagee-files-for-nasdaq-ipo-what-investors-need-to-know" target="_blank" rel="noreferrer noopener">China&#8217;s Chagee Files For US IPO; What Investors Need To Know </a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Nvidia, Moderna, Lucid, Dominari Holdings, Tesla: Why These 5 Stocks Are On Investors' Radars Today (CORRECTED)

Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna.
Looking at options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) we detected 38 trades.
If we consider the specifics of each trade, it is accurate to state that 57% of the investors opened trades with bullish expectations and 36% with bearish.
From the overall spotted trades, 30 are puts, for a total amount of $1,594,617 and 8, calls, for a total amount of $394,717.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $22.5 to $60.0 for Moderna over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Moderna's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Moderna's substantial trades, within a strike price spectrum from $22.5 to $60.0 over the preceding 30 days.
<h3>Moderna Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743445834_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$33.15</td>
<td>$33.15</td>
<td>$33.15</td>
<td>$60.00</td>
<td>$198.9K</td>
<td>215</td>
<td align="right">49</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.3</td>
<td>$6.15</td>
<td>$6.3</td>
<td>$30.00</td>
<td>$126.0K</td>
<td>1.0K</td>
<td align="right">215</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$8.45</td>
<td>$7.45</td>
<td>$8.45</td>
<td>$30.00</td>
<td>$114.0K</td>
<td>195</td>
<td align="right">228</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$15.45</td>
<td>$14.65</td>
<td>$14.65</td>
<td>$40.00</td>
<td>$84.9K</td>
<td>6.4K</td>
<td align="right">119</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$4.3</td>
<td>$4.25</td>
<td>$4.25</td>
<td>$31.00</td>
<td>$83.3K</td>
<td>258</td>
<td align="right">199</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
In light of the recent options history for Moderna, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Moderna Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 15,324,366, the MRNA's price is down by -8.44%, now at $28.5. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 31 days.</li>
</ul>
<h3>Expert Opinions on Moderna</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $36.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Underweight rating for Moderna, targeting a price of $33. 
&#x2A; Reflecting concerns, an analyst from Citigroup lowers its rating to Neutral with a new price target of $40.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Moderna's Options Frenzy: What You Need to Know

Risk sentiment remains under pressure at the start of the week on Wall Street, with tech-heavy indexes sliding while commodities advance, as traders fear a new wave of price pressures following <a href="https://www.benzinga.com/topic/tariffs">the upcoming tariffs announcement.</a>
The S&amp;P 500 experienced a turbulent morning session, first hitting its lowest level in over six months before clawing back some ground and trimming losses. Nevertheless, the benchmark equity index is on track for its worst month since September 2022, having fallen 7% in March.
Tech stocks remained the weakest link, with the Nasdaq 100 down 1.1% as semiconductor names weighed on the broader sector. The iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) dropped 1.9% and is down 11.9% month-to-date — also marking its worst month since September 2022.
President Donald Trump's threats toward Iran over the weekend pushed crude oil prices up by 3.5% for the session, marking the biggest single-day gain since October.
Energy-related stocks outperformed and are on pace to log their fourth consecutive positive month, now up 8.5% year-to-date.
Meanwhile, gold prices continued to smash record highs, with bullion surging over 1% to $3,115 per ounce. Quarterly gains have reached 18% — the strongest three-month rally since 2009.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) inched up 1.2% to $83,400, fighting to avoid a second consecutive monthly decline.
<h1 class="wp-block-heading">Monday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg %</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>41,688.45</td>
<td>0.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,555.01</td>
<td>-0.5%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,001.35</td>
<td>-1.0%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,075.33</td>
<td>-1.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:45 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.4% to $553.82.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) inched 0.2% up to $416.59.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;fell 1.1% to $463.82.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) tumbled 0.9% to $198.50.</li>
<li>The&nbsp;Energy&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 1.5%; the&nbsp;Technology&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) saw the worst performance, down 1.2%.</li>
</ul>
<h1 class="wp-block-heading">Monday&#8217;s Stock Movers</h1>
<ul>
<li>Celsius Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) surged more than 7% after Truist upgraded the stock from Hold to Buy and lifted its price target from $35 to $45.</li>
<li>Wolfspeed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) roared 11% following a 52% drop on Friday. </li>
<li>Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares plunged nearly 10% after the resignation of Dr. Peter Marks, the FDA's top vaccine official, sparked concerns over potential delays in the review of new treatments.</li>
</ul>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/etfs/25/03/44564323/tech-linked-etfs-suffer-outflows-in-march-as-ai-mini-bubble-pops-on-tariff-panic">Tech-Linked ETFs Suffer Outflows In March As AI &#8216;Mini Bubble&#8217; Pops On Tariff Panic</a></li>
</ul>
Photo: Shutterstock Professional via Shutterstock

CELH

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

WOLF

Stocks Fall, S&P 500 Eyes Worst Month In Almost Two Years, Oil Rallies: What's Driving Markets Monday?

Vaccine stocks are trading lower Monday following a shakeup at the <a href="https://www.benzinga.com/markets/25/03/44550801/rfk-jr-spreading-misinformation-and-lies-fdas-top-vaccine-official-walks-out-sparking-debate-on-safety-and-public-trust">U.S. Food and Drug Administration</a>.
What Happened: Peter Marks has resigned from his role at the FDA&#8217;s Center for Biologics Evaluation and Research. According to a Bloomberg<a href="https://www.bloomberg.com/news/articles/2025-03-31/vaccine-makers-plunge-after-fda-biologics-head-marks-steps-down?srnd=homepage-uk&amp;embedded-checkout=true"> report</a>, Marks was a top regulator at the FDA and played a key role in pushing quick approvals of vaccines during the Covid pandemic. 
Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares were down 13.5% at $26.88 and Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares were down 9.6% at $6.30 at last check. The SPDR S&amp;P Biotech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XBI#NYSE">XBI</a>) was down about 5.76% at publication time, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
The report indicates that Marks was also responsible for the FDA&#8217;s evaluation of cutting-edge treatments like cell therapies and gene therapies. He reportedly cited some issues with Health and Human Services Secretary Robert F. Kennedy Jr. in his resignation letter.
"I was willing to work to address the Secretary's concerns regarding vaccine safety and transparency," Marks reportedly said in the letter. 
"However it has become clear that truth and transparency are not desired by the Secretary, but rather he wishes subservient confirmation of his misinformation and lies."
Check This Out: <a href="https://www.benzinga.com/25/03/44560524/auto-stocks-skid-after-trump-shrugs-off-higher-prices-should-you-buy-the-dip">Auto Stocks Skid After Trump Shrugs Off Higher Prices &#8211; Should You Buy The Dip?</a>
The news comes after vaccine stocks came under pressure last week following reports The Trump administration plans to end financial support for vaccine alliance Gavi, which helps buy vaccines for children in developing countries. The Trump administration reportedly plans to cut billions in global health initiatives. 
Moderna was awarded $590 million by the U.S. Department of Health and Human Services (HHS) in January to continue developing a vaccine to protect against bird flu. The Trump administration was reportedly&nbsp;<a href="https://www.benzinga.com/25/02/43999106/trumps-officials-to-re-consider-modernas-590-million-bird-flu-vaccine-funding-hhs-cites-biden-administrations-failed-oversight" target="_blank" rel="noreferrer noopener">reconsidering that funding</a>&nbsp;as of last month.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/insights/options/25/03/44518123/modernas-options-frenzy-what-you-need-to-know">Moderna&#8217;s Options Frenzy: What You Need to Know</a></li>
</ul>
Photo: Shutterstock.

Movers

Moderna, Novavax Shares Are Tumbling Monday: What's Going On?

Moderna's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NYSE">MRNA</a>) short percent of float has risen 9.71% since its last report. The company recently reported that it has 46.88 million shares sold short, which is 16.84% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.16 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Moderna Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743426018_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Moderna has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Moderna's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Moderna's peer group average for short interest as a percentage of float is 5.27%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Moderna's Recent Short Interest

Events

Press Releases

Moderna to Present at Upcoming Conferences in March 2025

Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine

Flagship Pioneering Unveils Lila Sciences to Build Superintelligence in Science

Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform

Moderna Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults

Contracts

Flagship Pioneering Announces Agreement Between Pioneering Medicines and Pfizer to Discover Potential Novel, Selective Inhibitors for Autoimmune Disease

Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025

Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders

Flagship Pioneering Unveils Etiome to Pioneer Preemptive Healthcare

CTRX

FHTX

HPTX

SANA

TARS

ZSPH

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Morgan Stanley

JP Morgan

Citigroup

RBC Capital

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

Comments

Moderna

Noticias

Últimas noticias sobre Moderna (NASDAQ:MRNA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL